Gujarat Themis Biosyn Limited (GUJTHEM) fundamentals
Gujarat Themis Biosyn Limited is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as GUJTHEM (ISIN INE942C01045). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Gujarat Themis Biosyn Limited does
Gujarat Themis Biosyn Limited is an India-based company, which is principally engaged in the manufacturing of pharmaceuticals and medicinal chemical products. The Company is focused on the business of manufacturing and sale of finished active pharmaceutical ingredients (API) products by fermentation process. The Company operates through pharmaceuticals segment. Its product portfolio comprises Rifamycin-S and Lovastatin. The Company is manufacturing Rifamycin S, which is an intermediate for manufacturing the drug Rifampicin (an Antibiotic used for the treatment of several types of bacterial infections, including tuberculosis, Mycobacterium avium complex, leprosy, and Legionnaires' disease.) and Rifamycin O, which is an intermediate for manufacturing the drug Rifaximin (this is an Antibiotic used for treatment of traveler's diarrhea, irritable bowel syndrome, and hepatic encephalopathy).
Valuation and market data
| Last close | ₹422.65 |
|---|---|
| Market capitalisation | ₹4,601 crore |
| Enterprise value | ₹4,622 crore |
| P/E (TTM) | 0.00 |
| Price to book | 18.52 |
| Price to sales (TTM) | 0.00 |
| Book value per share | ₹22.82 |
| Dividend yield | 0.00% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Tue Feb 25 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹168 crore | ₹62 crore | ₹47 crore | 0.00 |
Figures are as reported (consolidated), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 70.9% |
|---|---|
| Foreign institutions (FII) | 1.8% |
| Mutual funds | 1.2% |
| Other domestic institutions | 0.0% |
| Retail and others | 26.2% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.